Skip to main content

Drug Composition Input

Enter your drug composition details to receive licensing requirements across different countries.

How it works

OntoPharma analyzes your drug composition and identifies the licensing requirements across multiple countries, saving you time and ensuring compliance.

  1. Enter your drug's composition details
  2. Select target countries for approval
  3. Review the AI-generated licensing steps
  4. Export detailed requirements for each market

Helpful Tips

Active Ingredients

Include all active pharmaceutical ingredients (APIs) with their exact quantities and units.

Excipients

List all inactive ingredients that serve as vehicles, binders, or preservatives.

Regulated Substances

Flag any controlled substances or ingredients with special regulatory considerations.

Multiple Countries

Select all target markets to receive comprehensive approval requirements for each jurisdiction.

View detailed documentation

Country Selection

Select countries and regions for drug licensing requirements analysis.

Select Countries

Major Regulatory Regions

US Food and Drug Administration

European Medicines Agency

Pharmaceuticals and Medical Devices Agency

Canadian health authority

Therapeutic Goods Administration

Medicines & Healthcare products Regulatory Agency

North America

Europe

Asia

South America

Oceania

Africa

Selected Countries

United States (FDA)
European Union (EMA)
Japan (PMDA)

3 countries selected

Regulatory Information

Each country has its own regulatory authority and specific requirements for drug approval. OntoPharma analyzes these requirements to provide a comprehensive licensing roadmap.

Key Regional Authorities

  • FDA: United States
  • EMA: European Union
  • PMDA: Japan
  • MHRA: United Kingdom

Selecting Multiple Countries

When selecting multiple countries, OntoPharma will identify opportunities for parallel submissions and streamlined regulatory pathways.

View regulatory guidelines

Regulatory Requirements

Comprehensive regulatory requirements for drug approval across selected countries.

Selected Countries

United States (FDA)

Last updated: June 15, 2023

Approval Pathway Overview

Based on the drug composition analysis, the following FDA approval pathway is recommended:

New Drug Application (NDA) - 505(b)(1)

Full approval pathway required for novel active ingredients. Expected review period: 10-12 months.

Required Documentation

Application Components

Form FDA 356h Application

Complete and submit FDA Form 356h (Application to Market a New or Abbreviated New Drug or Biologic for Human Use).

Chemistry, Manufacturing, and Controls (CMC)

Detailed information about drug composition, manufacturing process, and quality control procedures.

Nonclinical Pharmacology/Toxicology

Animal studies assessing safety, efficacy, and pharmacokinetics/pharmacodynamics.

Clinical Data

Results from Phase I, II, and III clinical trials demonstrating safety and efficacy in human subjects.

Risk Evaluation and Mitigation Strategy (REMS)

If applicable, a plan to manage known or potential serious risks associated with the drug.

Clinical Trial Requirements

Required Studies

Phase I: Safety and Dosage

Small group (20-100) of healthy volunteers or patients to determine safety and dosage.

Phase II: Efficacy and Side Effects

Larger group (several hundred) of patients to assess efficacy and side effects.

Phase III: Confirmatory Studies

Large-scale studies (several thousand) to confirm efficacy, monitor side effects, and compare to commonly used treatments.

Special Populations Studies

Additional studies may be required for pediatric, geriatric, or other special populations.

Labeling Requirements

Package Insert
  • • Full prescribing information
  • • Black box warnings (if applicable)
  • • Indications and usage
  • • Dosage and administration
  • • Contraindications
Medication Guide
  • • Patient-friendly language
  • • Significant risks and safety concerns
  • • Instructions for proper use
  • • Side effects reporting guidance

Post-Approval Requirements

  • Phase IV Studies

    Post-marketing surveillance to detect adverse effects not seen in clinical trials.

  • Adverse Event Reporting

    Mandatory reporting of serious adverse events through FDA's MedWatch program.

  • Manufacturing Inspections

    Periodic FDA inspections of manufacturing facilities to ensure compliance with cGMP.

  • Annual Reports

    Annual submission of updates on safety, efficacy, and manufacturing changes.

Ingredient-Specific Requirements

Special Requirements Detected

Based on your drug composition, the following special requirements apply:

  • Additional genotoxicity studies required for Compound X
  • Extended stability testing for formulation due to hydrolysis concerns
  • Control strategy required for potential impurity Y

Estimated Timeline

1
Pre-IND Meeting

Month 1-2: Initial consultation with FDA to discuss development plan

2
IND Submission

Month 3-6: Submit Investigational New Drug application

3
Clinical Trials

Month 7-30: Conduct Phase I, II, and III clinical trials

4
Pre-NDA Meeting

Month 31-32: Meet with FDA to discuss NDA submission

5
NDA Submission

Month 33-36: Prepare and submit New Drug Application

6
FDA Review

Month 37-46: FDA review period (standard review: 10 months)

FDA Approval

Month 47: Estimated approval date (if all requirements are met)

Additional Resources

FDA Guidelines Application Forms Fee Information Training Videos

Note: Regulatory requirements are subject to change. This information was last updated on June 15, 2023. Always verify with the official FDA website for the most current guidance.

Approval Timeline

Comprehensive timeline for drug approval process across selected regulatory authorities.

Timeline Controls

Regulatory Authorities

View Options

Time Range

Phase Filters

Drug Approval Timeline

Estimated Duration: 48 months Current Phase: Preparation
Legend:
FDA (US)
EMA (EU)
PMDA (Japan)
Critical Milestone
Optional Path
Phase / Activity
Jan-Mar Y1
Apr-Jun Y1
Jul-Sep Y1
Oct-Dec Y1
Jan-Mar Y2
Apr-Jun Y2
Jul-Sep Y2
Oct-Dec Y2
Jan-Mar Y3
Apr-Jun Y3
Jul-Sep Y3
Oct-Dec Y3
FDA (United States)
Pre-IND Meeting
2mo
IND Preparation
4mo
IND Review
30d
Phase I Clinical Trials
6mo
Phase II Clinical Trials
9mo
Phase III Clinical Trials
9-12mo
End of Phase II Meeting
EMA (European Union)
Scientific Advice
2mo
Pediatric Investigation Plan
5mo
Clinical Trials (EU Sites)
18mo
Pre-submission Meeting
2mo
PMDA (Japan)
Pharmaceutical Interview
2mo
Clinical Trial Notification
30d
Japanese Bridging Studies
10mo
PMDA Consultation
Parallel Strategy
NDA/MAA Preparation
6mo
FDA Submission/Review
10+
EMA Submission/Review
12+
PMDA Submission/Review
12+

Critical Path Analysis

Timeline Optimization Opportunities

  • Parallel Phase I trials across regions can save 3-4 months
  • Early scientific advice from EMA can significantly reduce review time
  • Rolling submission to FDA can accelerate review process by 1-2 months

Potential Delay Risks

  • Patient recruitment challenges in Phase III studies (+3-6 months)
  • Additional PMDA safety requirements for Japanese population
  • EMA pediatric investigation plan amendments

Expedited Pathway Opportunities

  • FDA Fast Track designation eligible (6-month review)
  • EMA PRIME (Priority Medicines) consideration
  • PMDA Sakigake designation possible for novel mechanism

Documentation Requirements

Complete list of documentation needed for drug approval submissions across regulatory authorities.

Document Checklist & Requirements

Status: Ready: 45 In Progress: 23 Missing: 12
Last updated: June 15, 2023

Administrative Documents

Document Required By Format Status Actions
Application Form
Official application form specific to each regulatory body
All Authorities
PDF/Electronic Submission
 Complete
Cover Letter
Formal letter describing the submission contents
All Authorities
PDF
 Complete
User Fee Form
Payment information for application review fees
FDA, EMA, PMDA
Agency-specific Form
 In Progress
Patent Information/Exclusivity
Patent certification and exclusivity requests
FDA, EMA, MHRA
PDF
 Missing

Chemistry, Manufacturing, and Controls (CMC)

Document Required By Format Status Actions
Drug Substance Information
Manufacturing process, controls, specifications
All Authorities
eCTD Module 3.2.S
 Complete
Drug Product Information
Formulation, manufacturing process, controls
All Authorities
eCTD Module 3.2.P
 Complete
Stability Data
Long-term and accelerated stability studies
All Authorities
eCTD Module 3.2.P.8
 In Progress

Nonclinical Documentation

Document Required By Format Status Actions
Pharmacology Studies
Primary and secondary pharmacology studies
All Authorities
eCTD Module 4.2.1
 Complete
Toxicology Studies
Single and repeat-dose toxicity studies
All Authorities
eCTD Module 4.2.3
 Complete
Carcinogenicity Studies
Long-term studies to assess carcinogenic potential
FDA, EMA, PMDA
eCTD Module 4.2.3.4
 Missing

Clinical Documentation

Document Required By Format Status Actions
Clinical Study Reports
Complete reports of all clinical studies
All Authorities
eCTD Module 5.3
 In Progress
Clinical Overview
Critical analysis of clinical data
All Authorities
eCTD Module 2.5
 In Progress
Clinical Summary
Detailed summary of clinical study results
All Authorities
eCTD Module 2.7
 Missing

Regional-Specific Requirements

Document Required By Format Status Actions
Risk Management Plan
EU-specific risk management plan
EMA, MHRA
eCTD Module 1.8.2
 In Progress
Pediatric Investigation Plan
EU-specific pediatric study plan
EMA
eCTD Module 1.10
 Missing
REMS (Risk Evaluation and Mitigation Strategy)
FDA-specific risk management program
FDA
eCTD Module 1.16
 Complete

Documentation Summary

Total Documents 80
Complete 45 (56%)
In Progress 23 (29%)
Missing 12 (15%)

Authority Readiness

FDA (United States) 90%
EMA (European Union) 65%
PMDA (Japan) 75%
MHRA (United Kingdom) 60%
Health Canada 40%

High Priority Actions

  • Complete Clinical Summary (Module 2.7)

    Required for all submissions

  • Finalize Carcinogenicity Studies

    Required for FDA, EMA, PMDA

  • Complete Stability Data Reports

    In progress, due in 30 days

  • Submit EU Risk Management Plan

    In progress, due in 45 days

Compliance Checklist

Track all required activities and compliance items across regulatory jurisdictions.

Compliance Requirements

Overall Compliance:
65%
Last updated: June 15, 2023

FDA Requirements (United States)

Requirement Category Deadline Status Actions
Acute Toxicity Studies
Single-dose studies in two mammalian species
Safety Assessment
Completed
 Completed
Repeat-Dose Toxicity Studies
28-day studies in rodent and non-rodent species
 Safety Assessment
Completed
 Completed
Genotoxicity Studies
Ames test and in vivo micronucleus assay
Safety Assessment
07/30/2023
 In Progress
Reproductive Toxicity Studies
Fertility and early embryonic development
Safety Assessment
08/15/2023
 Not Started
Primary Pharmacology
In vitro receptor binding studies
 Pharmacology
Completed
 Completed

EMA Requirements (European Union)

Requirement Category Deadline Status Actions
Maximum Residue Limits (MRL) Assessment
For veterinary products only
 Safety Assessment
Not Applicable
 Not Applicable
Environmental Risk Assessment
Environmental impact evaluation
 Environmental
Completed
 Completed
Preliminary Juvenile Toxicity Assessment
Required for products intended for pediatric use
 Safety Assessment
08/30/2023
 In Progress

Critical Compliance Items

Reproductive Toxicity Studies

Required for FDA submission, deadline in 30 days (08/15/2023)

Genotoxicity Studies

In progress, 70% complete, due on 07/30/2023

Preliminary Juvenile Toxicity Assessment

Required for EMA submission, 40% complete, due on 08/30/2023

Compliance Progress by Authority

FDA (United States)
75%
Preclinical: 75% Clinical: 80% Submission: 70%
EMA (European Union)
65%
Preclinical: 70% Clinical: 60% Submission: 65%
PMDA (Japan)
50%
Preclinical: 65% Clinical: 45% Submission: 40%
MHRA (United Kingdom)
60%
Preclinical: 65% Clinical: 60% Submission: 55%
Health Canada
55%
Preclinical: 70% Clinical: 50% Submission: 45%

Upcoming Compliance Deadlines

Genotoxicity Studies

Due in 15 days

Ames test and in vivo micronucleus assay

FDA Safety In Progress

Reproductive Toxicity Studies

Due in 30 days

Fertility and early embryonic development

FDA Safety Not Started

Preliminary Juvenile Toxicity Assessment

Due in 45 days

Required for products intended for pediatric use

EMA Safety In Progress

Generate & Export Report

Create comprehensive reports for different regulatory authorities and export in your preferred format.

Report Configuration

Formatting Options

Report Information

Drug Name
Rivaroxaban
Drug Type
Small Molecule
Therapeutic Category
Anticoagulant
Report Date
June 15, 2023
Generated By
OntoPharma AI Assistant

Recent Reports

  • FDA Requirements Report

    PDF · June 12, 2023

  • Global Regulatory Overview

    Word · June 5, 2023

  • Timeline Comparison Report

    Excel · May 28, 2023

  • Documentation Requirements

    PDF · May 15, 2023

Report Tips

  • Export to PDF for official submissions
  • Use Word format for editable reports
  • Excel format is best for detailed timelines
  • Include recommendations section for strategic insights

Report Preview

Drug Approval Requirements - Comprehensive Analysis

Rivaroxaban (Anticoagulant)

Generated by OntoPharma AI Assistant

June 15, 2023

Table of Contents

  1. Executive Summary
  2. Requirements Overview
  3. Approval Timeline
    1. FDA (United States)
    2. EMA (European Union)
    3. PMDA (Japan)
  4. Required Documentation
  5. Fees & Costs
  6. Recommendations

1. Executive Summary

This report provides a comprehensive analysis of the regulatory requirements for obtaining marketing approval for Rivaroxaban across major global markets. The analysis is based on the drug's composition and therapeutic classification as an anticoagulant.

Rivaroxaban falls under the small molecule drug category and will require standard New Drug Application (NDA) pathways in most jurisdictions. The estimated timeline for full global approval ranges from 12-36 months, with the FDA potentially offering the fastest approval pathway...

[Preview truncated]

2. Requirements Overview

[Requirements comparison chart will appear here]

[Preview truncated]

© 2023 OntoPharma AI-Powered Drug Licensing Assistant

This report is generated based on current regulatory information and may require verification with official sources.

Settings

Configure your preferences and manage your account settings.

Need Help?

Visit our help center for more information about configuring your account settings.

Profile Information

JD

Application Preferences

Theme

Default Dashboard View

Features

View detailed analytics about your drug approval processes.

Receive AI-powered suggestions to optimize your approval process.

Export reports in various formats including PDF, Excel, and Word.

API Keys

Manage your API keys to integrate OntoPharma services with your internal systems.

Name Key Created Status Actions
Development API Key
••••••••••••••••63f9
May 12, 2023 Active
Production API Key
••••••••••••••••7a2d
June 3, 2023 Active

Security Settings

Change Password

Two-Factor Authentication

Add an extra layer of security to your account

Not Enabled

Sessions

Device Location Last Active Action
Chrome on Windows
Current Session
New York, US
192.168.1.1
 Just now This device
Safari on iPhone
Mobile
Boston, US
198.51.100.42
 3 days ago
Apollo
Chat on WhatsApp
LinkedIn Logo Chat on LinkedIn